Study Name Principal Investigator
(APOLLO) The APOL1 Long-term Kidney Transplantation Outcomes Network- APOLLO Study Gani, Imran
(ASCEND-ID) 52 week open-label (sponsor blind), randomized, active controlled, parallel group, multi-center study to evaluate the efficacy and safety of Daprodustat compared to recombinant human erythropoietin in subjects with anemia associated with chronic kidney disease who are initiating dialysis Mulloy, Laura
(Gel) A Two-part, Multicenter, Dose-titration Study Evaluating the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Oxybutynin Chloride 10% Gel for the Treatment of Detrusor Overactivity Associated With a Neurological Condition in Pediatric Patients Morganstern, Bradley
(KEYLYNK-010) A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy Parikh, Jigarkumar
(KEYNOTE-641) A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Parikh, Jigarkumar
(KEYNOTE-921) A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-nave Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) Parikh, Jigarkumar
(Lionheart21) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection Mallavarapu, Ravi
(MK7339-002) A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer Nayak-Kapoor, Asha
(Natural History) A Natural History Study of Patients with Biopsy-proven Focal Segmental Glomerulosclerosis and Proteinuria Who Are of Recent African Ancestry or Have 2 APOL1 Risk Alleles Mulloy, Laura
(OKRA) Evaluation of Patient Outcomes From the Kidney Allograft Outcomes Allosure Registry Gani, Imran
(Paisley) A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis Mulloy, Laura
AVA-CIT-330: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancer Ghamande, Sharad
CDX1140-01: A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies Kota, Vamsi
Comparing number of injection sites of in-office intravesical Onabotulinumtoxin A treatments for overactive bladder: a randomized controlled trial Lanzer, Jennifer
Effect of Nutritional Status on APOL1 Variants Chronic Kidney Disease (Pilot Study) Anglin, Judith
Kadmon KD025-013: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study) Kota, Vamsi
S1605; Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Ghamande, Sharad
SGN22E-001: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy Parikh, Jigarkumar
Translational Research in Benign and Malignant Genitourinary, Gastrointestinal, and Breast Diseases. Lokeshwar, Vinata
Using a humanized mouse model to predict which potential living donor is immunologically the best match for a prospective living donor kidney transplant recipient. Mulloy, Laura